ClinConnect ClinConnect Logo
Search / Trial NCT06861140

Exploring the Influence of Trptophan on the Treatment of Pouchitis

Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Mar 1, 2025

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Pouchitis Antibiotics Probiotics Tryptophan Metabolites

ClinConnect Summary

The "Try Pro Pouch" study is looking at how a substance called tryptophan, which is found in many everyday foods, might help improve treatment for pouchitis. Pouchitis is a condition that causes inflammation in the intestines for patients who have had surgery to create a pouch. Currently, this condition is often treated with antibiotics and probiotics, but these methods do not always prevent the inflammation from coming back and can sometimes lead to antibiotic resistance. This trial will compare the effects of a high-tryptophan diet with a placebo (a treatment that doesn't contain any active ingredients) to see if it helps reduce the recurrence of pouchitis.

To qualify for this study, participants need to be at least 18 years old and have a diagnosis of pouchitis that requires antibiotic and probiotic treatment. However, people who have major surgery planned during the study or are at high risk of malnutrition won't be eligible to join. If chosen to participate, individuals can expect to follow a specific diet and be monitored to see how the addition of tryptophan affects their pouchitis symptoms. This research aims to find new ways to help manage pouchitis more effectively and improve patients’ quality of life.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Pouchitis (PDAI \>= 7)
  • indication for the application of antibiotics and probiotics
  • Age \>=18 years
  • Informed consent
  • Exclusion Criteria:
  • major surgery planned druing the intervention
  • high risk for malnutrition (NRS 2002 \>=3/ BMI \<18,5 kg/m\^2)

About Universitätsklinikum Hamburg Eppendorf

Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.

Locations

Patients applied

0 patients applied

Trial Officials

Samuel Huber, Prof. Dr. med.

Principal Investigator

Universitätsklinkum Hamburg-Eppendorf, I. Medizinische Klinik und Poliklinik

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported